Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC)

Conclusions: TMB is a promising biomarker, which can predict the efficacy of ICI therapy in advanced NSCLC patients, included ORR, DCR, PFS and OS.

Source: Journal of Cancer - January 15, 2021 Category: Cancer & Oncology Authors: Xiaoting Ma, Yujian Zhang, Shan Wang, Jing Yu Tags: Research Paper Source Type: research